Five ways weight-loss jabs are changing spending habits

Uptake of GLP-1 weight-loss injections — estimated at about 1.6 million UK users in 2024 — is materially shifting consumer spending patterns: supermarkets (Co-op, Morrisons, M&S, Ocado) are launching nutrient-dense and smaller-portion products, restaurants and takeaways are seeing reduced frequency, and alcohol purchases among households with GLP-1 users fell by 15 percentage points in a Worldpanel study. Private treatment costs vary (users report around £186–£300+ per month), and ancillary demand is rising for fashion replacement, gyms and aesthetic procedures (an 8% rise in facelift demand in 2024), implying sectoral winners (fitness, certain retail categories, non-alcoholic beverages) and losers (casual dining, alcohol incumbents) that investors may want to monitor.

Analysis

Market structure: GLP-1 adoption (≈1.6m UK users today, ~2–3% penetration) is shifting spend away from volume food/alcohol and toward nutrient-dense groceries, fashion replacement, beauty/fitness and elective procedures. Winners are specialty protein/snack SKUs, premium/responsive supermarkets (OCDO.L, MKS.L, Sainsbury’s/TSCO.L) and fast-growth secondhand/fashion platforms; losers are high-frequency casual dining, big-ticket takeaways and mass alcohol producers (short-term demand headwinds ≈10–20% less visits among users). Pricing power will bifurcate: supermarkets can extract higher ASPs for nutrient-dense SKUs while restaurants with fixed-cost footprints face margin pressure.

Risk assessment: Tail risks include regulatory pushback (NHS restriction or safety alerts) that could halve adoption within 6–12 months, or supply shocks raising private costs >50% and curbing repeat use. Immediate risks (days–weeks) are sentiment/news and quarterly retail data; medium (3–12 months) hinge on reimbursement/policy and supply; long-term (1–3 years) depends on cultural adoption and substitution rates. Hidden dependencies: discretionary spend reallocation could offset declines (e.g., spend moves from dining to fashion/fitness), masking revenue impact in aggregate retail sales.

Trade implications: Direct plays: overweight listed gyms/fitness (GYM.L) and online/fast-fashion/secondhand beneficiaries (ASC.L, BOO.L, EBAY) and select supermarkets (OCDO.L, MKS.L) on 3–12 month horizons; underweight casual dining/pubs (JDW.L, MAB.L) and large alcohol brewers (DGE.L) with 6–12 month view. Use pair trades (long ASC.L + short JDW.L) to capture rotation; consider 6–12 month call spreads on GYM.L and put spreads on JDW.L to control capital.

Contrarian angles: Consensus focuses on pharma winners (NVO/LLY) but underprices downstream retail reconfiguration and resale market tailwinds — secondhand clothing and niche cosmetics/ aesthetics providers may see 20–40% revenue velocity uplift locally. The market may overreact to short-term dine-out metrics; restaurants that successfully reprice smaller-portion, premium-margin menus can recoup revenue within 2–4 quarters. Monitor NICE/NHS policy, pharma supply notices and monthly grocery/alcohol volume data as high-signal catalysts.

Key Decisions for Investors

• Establish a 2–3% long position in GYM.L (The Gym Group) within 4–8 weeks; target +25–35% total return in 12 months driven by membership growth and higher ancillary spend, use 6–9 month call spreads (buy 6–9 month ATM calls, sell 6–9 month +15% calls) to cap cost.
• Initiate a 2% long exposure to OCDO.L and MKS.L (split) as a paired bet on premium small-portion/nutrient-dense SKU mix; average in on any pullbacks >8% over next 3 months and target 12–18% upside by H2 2026 as assortment premiuming lifts gross margins.
• Open a 1.5% short or buy 6–12 month put protection on JDW.L and MAB.L (combined) to express lower dine-out frequency; size modestly (1–1.5%) given execution risk, target 15–25% downside over 6–12 months if monthly footfall declines persist >10%.
• Establish a 1–2% long position in ASC.L or BOO.L and/or EBAY (split) to capture secondhand/fashion rotation; layer in if GLP-1 UK user penetration doubles from ~2–3% to >5% within 12 months (monitor monthly traffic and app installs as trigger).
• Monitor catalysts: within 30–90 days, track (a) any UK NICE/NHS guidance on GLP-1 reimbursement, (b) pharma supply alerts (Novo/NVO, Lilly/LLY), and (c) monthly grocery and alcohol volumes — if public funding expands or supply stabilizes, increase long exposure to retail/fashion/fitness by +1–2%.